Treatment of fatty liver disease
AssigneeAvogadro Development Corp.
InventorsSteven B. Landau, Christopher R. Shepard
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of treating fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′. The fatty liver disease can be non-alcoholic fatty liver disease, such as simple fatty liver disease or NASH. The invention also relates to the use of adiponectin as a biomarker for identifying subjects more likely to respond to treatment with the compound on Formula (I) 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′ and for assessing response of the subject during treatment with the compound of Formula (I) 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′.
Claims17
A method of treating a fatty liver disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound represented by Formula (I):
- 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′ (I)
- or a pharmaceutically acceptable salt thereof
- wherein, N1 through N6 and N11 through N16, each independently, is a 2′-deoxoribonucleoside;
- N7, N8, N17, and N18, each independently, is a ribonucleoside;
- dCm is a 5-methyl-cytosine 2′-deoxoriboside of the following structural formula:
- dGc is a 7-deaza-guanine 2′-deoxoriboside of the following structural formula:
- and
- any two adjacent ribonucleosides are covalently linked by either a phosphodiester or a phosphorothioate linker.
A method of identifying the likelihood of a fatty liver disease in a subject to be responsive to administration of a compound of Formula (I):
- (I)
- 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′
- or a pharmaceutically acceptable salt thereof wherein, N1 through N6 and N11 through N16, each independently, is a 2′-deoxoribonucleoside;
- N7, N8, N17, and N18, each independently, is a ribonucleoside;
- dCm is a 5-methyl-cytosine 2′-deoxoriboside of the following structural formula:
- dGc is a 7-deaza-guanine 2′-deoxoriboside of the following structural formula:
- and
- any two adjacent ribonucleosides are covalently linked by either a phosphodiester or a phosphorothioate linker, the method comprising:
- a) obtaining or providing a plasma sample from a subject having a fatty liver disease;
- b) measuring the plasma adiponectin level in the sample;
- and
- c) comparing the plasma adiponectin level to a control level of adiponectin;
- wherein if the plasma adiponectin level is less than the control level the fatty liver disease is identified as being more likely to be responsive to the administration of the compound of Formula (I).
A method of assessing the efficacy of treating fatty liver disease with a compound of Formula (I) in a subject in need thereof:
- (I)
- 5′-N1N2N3N4N5N6-N7N8-dCm-dGc-N11N12N13N14N15N16-N17N18-3′
- or a pharmaceutically acceptable salt thereof wherein,
- N1 through N6 and N11 through N16, each independently, is a 2′-deoxoribonucleoside;
- N7, N8, N17, and N18, each independently, is a ribonucleoside;
- dCm is a 5-methyl-cytosine 2′-deoxoriboside of the following structural formula:
- dGc is a 7-deaza-guanine 2′-deoxoriboside of the following structural formula:
- and
- any two adjacent ribonucleosides are covalently linked by either a phosphodiester or a phosphorothioate linker, for treating fatty liver disease the method comprising:
- a) detecting in a subject plasma sample at a first point in time the level of adiponectin;
- b) repeating step a) during at least one subsequent point in time after administration of the compound represented by Formula (I);
- and
- c) comparing the levels detected in steps a) and b), wherein an increased level of adiponectin relative to at least one subsequent subject plasma sample, indicates that the compound of Formula (I) treats the fatty liver disease in the subject.
Dependencies are inferred from the claim text.